Robertson Stephens Raises Estimates on Amgen

Analyst Michael King Jr. cites the biotech company's accelerating product sales

Robertson Stephens raised its estimates on Amgen (AMGN ) partly on the biotechnology firms's accelerating product sales. The company said its expects earnings per share to rise 20% in 2002 and sees compounded annual growth rate in the low-20% range for sales and earnings per share through 2005.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.